Teva launches generic schizophrenia, bipolar disorder drug
NORTH WALES, Pa. — Teva Pharmaceuticals has launched a generic version of a psychiatric drug, the company said Friday.
Teva announced the launch of olanzapine orally disintegrating tablets in the 5-mg, 10-mg, 15-mg and 20-mg strengths in blister packs of 30.
The drug is a generic version of Eli Lilly’s Zyprexa Zydis, used to treat schizophrenia and bipolar disorder.
Eli Lilly did make $65 billion on Zyprexa and they still expect to capture 20% of the US market as well as a billion year on Zyprexa XR.- Association Between Zyprexa and Hyperglycemia. There is concern Zyprexa,like other atypical antipsychotic drugs, has the potential to cause metabolic disorders, particularly hyperglycemia (excess sugar) and diabetes. Atypical antipsychotics cause the body to metabolize fat instead of carbohydrates, leading to insulin resistance to the excess carbohydrates. At the same time they promote fat accumulation.I was a patient back in 1996-2000 who was a subject of Eli Lilly's Zyprexa 'viva' Zyprexa' off label sales promotion.I was given it as an ineffective costly treatment for PTSD It gave me diabetes as a side effect.--Daniel Haszard
American Diabetes Association appoints chief scientific and medical officer
ALEXANDRIA, Va. — The American Diabetes Association has appointed Robert Ratner to serve as chief scientific and medical officer of the organization, effective May 7.
In his role, Ratner will serve as the primary medical and scientific representative and spokesman for the association’s scientific and medical affairs, research program and other clinical activities. Ratner also will oversee the planning, development and implementation of a wide variety of strategic scientific and medical programs to support and advance the association’s mission. He currently serves as a professor of medicine at Georgetown University Medical School and senior research scientist at the MedStar Health Research Institute.
"Bob Ratner is one of the brightest and most respected minds in diabetes," American Diabetes Association CEO Larry Hausner said. "He brings a remarkable breadth of experience to this vital role, and I am confident that his leadership and vision will be a strong guiding force in helping the Association achieve our strategic priorities and further our mission."
No comments found
Regulatory waiting period for Bristol’s Inhibitex acquisition expires
NEW YORK — The regulatory waiting period standing between Bristol-Myers Squibb and its acquisition of drug maker Inhibitex has expired, giving Bristol the green light to buy the company.
Bristol said Friday that the expiration of the waiting period, mandated by the Hart-Scott-Rodino Antitrust Improvement Act of 1976, would allow it to acquire Inhibitex for $26 per share.
The New York-based drug maker announced its plan to buy Alpharetta, Ga.-based Inhibitex for $2.5 billion early last month. Inhibitex develops drugs for treating hepatitis C, including INX-189, currently in phase-2 trials.
No comments found